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Tubercidin (TUB) is a toxic adenosine analog with potential antiparasitic activity against
Leishmania, with mechanism of action and resistance that are not completely understood.
For understanding the mechanisms of action and identifying the potential metabolic
pathways affected by this drug, we employed in this study an overexpression/selection
approach using TUB for the identification of potential targets, as well as, drug resistance
genes in L.major. Although, TUB is toxic to the mammalian host, these findings can provide
evidences for a rational drug design based on purine pathway against leishmaniasis.
Methodology/Principal findings
After transfection of a cosmid genomic library into L.major Friedlin (LmjF) parasites and
application of the overexpression/selection method, we identified two cosmids (cosTUB1
and cosTU2) containing two different loci capable of conferring significant levels of TUB
resistance. In the cosTUB1 contained a gene encoding NUPM1-like protein, which has
been previously described as associated with TUB resistance in L. amazonensis. In the cos-
TUB2 we identified and characterized a gene encoding a 63 kDa protein that we denoted as
tubercidin-resistance protein (TRP). Functional analysis revealed that the transfectants
were less susceptible to TUB than LmjF parasites or those transfected with the control vec-
tor. In addition, the trpmRNA and protein levels in cosTUB2 transfectants were higher than
LmjF. TRP immunolocalization revealed that it was co-localized to the endoplasmic reticu-
lum (ER), a cellular compartment with many functions. In silico predictions indicated that
TRP contains only a hypothetical transmembrane domain. Thus, it is likely that TRP is a
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lumen protein involved in multidrug efflux transport that may be involved in the purine meta-
bolic pathway.
Conclusions/Significance
This study demonstrated for the first time that TRP is associated with TUB resistance in
Leishmania. The next challenge is to determine how TRP mediates TUB resistance and
whether purine metabolism is affected by this protein in the parasite. Finally, these findings
may be helpful for the development of alternative anti-leishmanial drugs that target purine
pathway.
Author Summary
The identification of genes associated with drug resistance has contributed for understand-
ing of the mechanisms of action of compounds against Leishmania, as well as, in the iden-
tification of the resistance mechanisms mediated by the proteins encoded by these genes.
Differently from the mammalian host, Leishmania is unable to synthetize purine nucleo-
tides de novo and must rescue preformed purines from its host. Due to this metabolic dif-
ference between host and parasite, the purine metabolism can be considered as a potential
target for drug targeting. TUB is a toxic adenosine analog that was already demonstrated
as effective against Leishmania. Using a strategy of gene overexpression after cosmid geno-
mic library transfection, we isolated, mapped, sequenced and identified two genes involved
in TUB resistance in L.major. In one of the cosmids, we identified NUPM1-like protein,
an atypical multidrug resistance protein previously described in L. amazonensis involved
in TUB resistance. The other cosmid contains a novel resistance marker involved in TUB
resistance, described here as the TRP. Co-localization of TRP in the ER of LmjF and in sil-
ico structural predictions indicated that TRP might be an ER lumen protein. Our findings
may be useful to elucidate the purine pathway in the parasite and to understand the role of
TRP in the mechanism of TUB resistance.
Introduction
Leishmania spp. are the causative agents of leishmaniasis, a parasitic protozoan disease that
affects 12 million people worldwide with an estimated annual incidence of approximately 1
million, including both visceral and cutaneous cases [1].
The leishmaniasis chemotherapy is complicated because most of drugs used are expensive,
toxic, and require long periods of supervised therapy [2]. Pentavalent antimonial is the WHO-
recommended drug for the treatment of leishmaniasis; however, it has several side effects and
reports of parasite resistance have been described worldwide [3]. Cases that are unresponsive
to antimonial treatment are usually treated with amphotericin or pentamidine, although these
drugs also have several side effects [3]. Miltefosine is the first effective oral drug developed to
treat visceral leishmaniasis. It has been used in India for more than a decade [4] and an increase
in the failure rate has been reported [5, 6].
Considering the limitations of the currently used chemotherapy and the lack of effective
vaccines for the leishmaniasis, the identification of new drugs and vaccine approaches for the
treatment of leishmaniasis is required. A rational strategy for chemotherapeutic exploitation
in parasitic diseases can be developed, based on the identification of fundamental metabolic
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differences between parasite and host. New potential drug targets have been identified in
molecular and biochemical studies to identify potential targets of the parasite that can be used
in future therapies [7, 8].
An interesting pathway for exploration in the parasite is the purine metabolism. Purine
nucleotides and their derivatives are precursors of a variety of cellular and metabolic processes,
including energy production, cell signaling, synthesis of nucleic acids, modulation of enzymatic
activities and synthesis of co-enzymes [9–11]. Leishmania and other protozoan parasites are
unable to synthesize purine nucleotides de novo and must salvage them from the host [10].
This unique characteristic may be the basis for the susceptibility of Leishmania to purine ana-
logs [12, 13]. Purine uptake in Leishmania is required for parasite viability during all life cycle
stages [14]. Parasite nucleoside transporters, located on the plasma membrane, perform an
essential function in uptake of purine nucleosides from the host into the parasite, which is the
first step in the salvage process [15].
TUB is a toxic adenosine analog that is incorporated into nucleic acids in microorganisms
and in mammalian cells. TUB has been previously described as a potential antiparasitic agent
due to its inhibition of purine uptake in Schistosoma mansoni, S. japonicum [16, 17], Trypano-
soma gambiensi [18] and Leishmania spp. [19, 20].
Considering the potential antiparasitic activity of TUB, in this study we aimed to identify
the potential loci involved in TUB resistance in L.major. This knowledge is essential to under-
stand the mechanism of action and resistance of this compound, as well as for identifying
potential drug targets in the parasite. Accordingly, an overexpression/selection method with
cosmid genomic libraries of LmjF was used to isolate two loci involved in TUB resistance [21].
One of the isolated cosmids (cosTUB1) contains a locus encoding NUPM1, a putative tran-
scription-factor-like protein, previously described as toxic nucleoside resistance (TOR) [22].
TOR was described in L. amazonensis promastigote mutants resistant to TUB after drug selec-
tion in vitro, as an atypical multidrug resistance protein [22–24]. The other isolated cosmid
(cosTUB2) contains a locus involved in TUB resistance following overexpression. This locus is
not related to the tor gene or to other previously described locus involved in drug resistance in
Leishmania [21]. Interestingly, these two loci are associated with two different resistance pro-
files: while tor also confers resistance to both inosine dialdehyde and allopurinol, the other
locus confers resistance to inosine dialdehyde and hypersensitivity to allopurinol [21].
Based on these previous findings, in this study, we mapped, sequenced the genomic regions
of two cosmids (cosTUB1 and cosTUB2) and identified the two genes related to TUB resistance
in LmjF. TUB resistance gene in cosTUB1 encodes the previously described TOR protein,
while the locus in cosTUB2 encodes a hypothetical protein. Of the 8,272 protein-coding genes
predicted and annotated in LmjF genome, approximately 50% are annotated as hypothetical
proteins; most of them are likely involved in essential cellular processes [25, 26]. Thus, the
identification and characterization of TRP, may contribute for increasing the understanding of
the purine pathway in Leishmania and the role of this protein in drug resistance mechanisms.
Methods
Parasite strain, culture and drugs
Leishmania major Friedlin (LmjF) strain (MHOM/IL/1980/Friedlin) promastigotes were
grown at 25°C in M199 medium supplemented with L-glutamine, 10% heat-inactivated fetal
calf serum, 0.25% hemin, 12 mMNaHCO3, 100 μM adenine, 40 mMHEPES, 50 U/mL penicil-
lin and 50 μg/mL streptomycin. TUB, allopurinol, pentamidine, hygromycin B (HYG) and
G418 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Transfected parasites were
Tubercidin Resistance in Leishmania
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004972 September 8, 2016 3 / 21
cultured in M199 medium supplemented with increasing concentrations of HYG (125 to
500 μg/mL) or G418 (32 to 500 μg/mL), depending on the drug resistance marker.
Cosmid libraries and transfections
Cosmids cosTUB1 and cosTUB2 associated with TUB resistance were previously isolated by
an overexpression/selection strategy in LmjF as described by Cotrim et al. [21]. Briefly, two
genomic libraries containing 30–40 kb inserts of genomic DNA from LmjF strain constructed
in the shuttle vector cLHYG [27] were prepared by shearing or Sau3A partial digestion [21].
After transfection of these two cosmid libraries, parasites were plated on semisolid media in
the presence of two independent concentrations of TUB (0.9 and 1.8 μM). A total of 39 colo-
nies obtained after 10–15 days of incubation were then transferred to M199 liquid medium
containing increasing concentrations of HYG (from 125 to 500 μg/mL) to increase the cosmid
copy number [21]. Cosmid DNA was recovered from these primary TUB-resistant transfec-
tants, used to transform into Escherichia coli DH5α strain and analyzed by restriction enzyme
digestion [21]. Southern blot analysis confirmed the presence of two independent loci involved
in TUB resistance, one containing tor gene and the other corresponding to a new locus.
To confirm the role in TUB resistance, cosTUB1 and cosTUB2 were transfected back into
LmjF and after increasing cosmid copy number, tested for TUB resistance. Deletions of cos-
TUB1 and cosTUB2 were generated by partial digestion with KpnI and ApaI, respectively, fol-
lowed by self-ligation, to identify the gene(s) involved in TUB resistance. A pTRP construct
was generated by total digestion of cosTUB2 with ClaI and EcoRV restriction enzymes, fol-
lowed by ligation of the 3 kb fragment into the pSNBR vector [28], previously digested with the
same enzymes. Transfections were performed as described by Coburn et al. [29]. Promastigotes
from the late logarithmic phase were harvested, washed and resuspended in electroporation
buffer. A total of 20–40 μg of cosmid and plasmid DNA was mixed on ice with 4x107 cells in a
2-mm cuvette and subjected to electroporation (500 μF, 2.25 kV/cm) using a Bio-Rad Gene
Pulser apparatus. Mock transfection was performed in absence of cosmid or plasmid DNA for
the negative control while the transfection with cosmid or plasmid DNA of empty vector was
performed as control. Transfected parasites were kept on ice for 10 minutes and then trans-
ferred to 10 mL M199 medium. The antibiotics HYG or G418 were added after 24 hours,
depending on the drug resistance marker.
Analysis of drug susceptibility
For drug susceptibility analysis, promastigotes (106 promastigotes/mL) were incubated at 25°C
in the presence of increasing TUB concentrations for 72 hours, and then the number of para-
sites was determined using a Coulter T890 (Beckman, CA, USA). The 50% inhibitory concen-
tration (IC50) was measured at the time when control cultures lacking the drug had reached the
late logarithmic phase of growth [30, 31]. The results are expressed as the means ± standard
error. Statistical analysis was performed using the non-parametric Kruskal-Wallis test and
p< 0.05 was considered significant.
Identification of TUB-resistance-related loci and nucleotide sequencing
To identify the genomic region of interest in L.major genome databases, a 1.0 kb EcoRI frag-
ment from cosTUB1 and a 1.0 kb EcoRV fragment from cosTUB2 were subcloned into a pUC-
π vector. The subcloned fragments were sequenced using a MegaBACE 1000 automated
sequencer (GE Healthcare, UK) with DYEnamic Dye Terminator kit (GE Healthcare, UK),
according to the manufacturer’s instructions. Analyses of the nucleotide sequences were per-
formed using Lasergene Software (DNASTAR, Inc.) and Clone Manager 9 Software. Sequence
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data for the remaining regions were obtained from LmjF GeneDB [25]. Nucleotide sequences
obtained were used to map the genomic region corresponding to the two different loci using
LmjF database. In silico analyses were also conducted to estimate the insert sizes of both cos-
mids after digestion with different restriction enzymes.
In silico analysis and protein prediction
In silico analysis of the genomic regions involved in TUB resistance was performed using
DNASTAR and Clone Manager 9 Software. BLAST searches of LmjF GeneDB [25] and Tri-
TrypDB [32] were performed using the standard settings. Multiple alignments were performed
using the Constraint-based Multiple Protein Alignment Tool (Cobalt) [33]. Prediction of trans-
membrane domains was performed with the TMHMM Server [34, 35] while the predictions of
protein function, sub-cellular localization and the tridimensional TRP structure were per-
formed using ProtFun [36, 37], TargetP Server [38, 39] and Phyre2 [40], respectively.
The sequence data described in this paper are available under the following accession num-
bers: XM_001685128.1 for gene ID LmjF.31.1940 (nupm1), and XM_001685135.1 for gene ID
LmjF.31.2010 (trp). All sequence data are also available at www.tritrypdb.org.
Total RNA isolation and RT-qPCR
Total RNA from promastigotes in stationary growth phase and during the growth curve on
days 3, 5, 7 and 9, were isolated using TRIzol reagent (Life Technologies, Carlsbad, CA, USA),
according to the manufacturer’s instructions. RNA samples were treated with DNase I
(Thermo Scientific, Lithuania, EU) and RNA concentration and purity were determined using
a spectrophotometer at A260/A280 (Nanodrop ND1000, Thermo Scientific, USA). Reverse
transcription was performed using 2 μg of total RNA as template, reverse transcriptase and
random primers (cDNA synthesis kit, Thermo-Scientific, Canada), according to the manufac-
turer’s instructions. Equal amounts of cDNA were run in triplicate in a total volume of 25 μL
containing Power SYBR Green Master Mix (Life Technologies, Warrington, UK) and the
following primers (10 μM): TRP_F 5´-CGGTGTAGATGAACCAGCAGTAG-3´, TRP_R
5´-CTCACAGAGGGATTTCGAGAGTG-3´, GAPDH_F 5´-AACGAGAAGTTCGGCA
TAGTCGAG-3´ and GAPDH_R: 5´-ACTATCCACCGTCTTCTGCTTTGC-3´. The mixture
was incubated at 94°C for 5 minutes, followed by 40 cycles at 94°C for 30 sec, 64°C for 30 sec
and 72°C for 30 sec. A negative control in the absence of reverse transcriptase was included in
RT-qPCR assays for check DNA contamination in RNA samples. Reactions were carried out
using an Exicycler 96 (Bioneer, Daejeon, Korea). The copy number of the target gene (trp) and
housekeeping gene (gapdh) were quantified in three biological replicate samples, considering
the molar mass concentration, according to a standard curve generated from a ten-fold serial
dilution of a quantified and linearized plasmid containing the target fragment for each quanti-
fication test. The normalized trp/gapdh ratio of the absolute number of molecules of each target
was used as parameter of the relative expression of trp in the cosTUB2 and pTRP transfectants
relative to LmjF or the line transfected with the empty vector (pSNBR or cLHYG). Analyses
were performed using Analysis Exicycler3 Software (Bioneer, Daejeon, Korea).
Cloning, expression and purification of TRP, and production of a rabbit
anti-TRP polyclonal antibody
The open reading frame (ORF) of gene trp (LmjF.31.2010) was amplified by PCR using the fol-
lowing primers containing the restriction enzyme sites for BamHI and NotI (underlined):
TRP_F_BamHI 5´-GGATCCATGGAGTGCATCAACCAAGAGAGC-3´ and TRP__R_NotI
5´-GCGGCCGCTCACATGGCACAGATAAACACC-3´. The amplified fragment was cloned
Tubercidin Resistance in Leishmania
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004972 September 8, 2016 5 / 21
into the pET28a (Novagen, USA) expression vector and sequenced to confirm the insertion
direction. The pET-TRP plasmid obtained was then used to transform into E. coli (BL21(DE3)
CodonPlus-RIL). Selected clones were grown aerobically at 37°C in LB medium containing
kanamycin (30 μg/mL) and chloramphenicol (35 μg/mL) to a culture OD600 0.6–0.8. pET-TRP
expression was induced by 1 mM of isopropyl-β-D-thiogalactopyranoside. After induction, the
culture was lysed by sonication (Sonics–VCX500) with 20 mM sodium phosphate, 500 mM
sodium chloride and 5 mM imidazole. Lysed samples were clarified by centrifugation at 10,000
x g, for 15 minutes at 4°C, and inclusion bodies were solubilized with 20 mM sodium phos-
phate, 500 mM sodium chloride, 5 mM imidazole and 8 M urea. Recombinant TRP was
obtained by affinity chromatography with a 1 mL HisTrap HP column (GE Healthcare, Upp-
sala, Sweden). The purified recombinant TRP was analyzed by SDS-PAGE and then used to
produce a rabbit polyclonal anti-TRP antibody by Proteimax Biotechnology (Sao Paulo,
Brazil).
Western blot analysis
Approximately 107 promastigotes in the stationary growth phase and during the growth curve
on days 3, 5, 7 and 9 were washed with PBS and then lysed with lysis buffer (100 mM Tris-HCl
pH 7.5, 2% Nonidet P40, 1 mM PMSF and protease inhibitor cocktail (Sigma-Aldrich, St
Louis, MO, USA)). Cells were disrupted by ten freeze/thaw cycles in liquid nitrogen and 42°C,
and were then cleared of cellular debris by centrifugation at 12,000 x g for 15 minutes at 4°C.
Equal amounts of total protein (25 μg) were solved using SDS-PAGE and transferred to a nitro-
cellulose membrane (Hybond-C, Amersham Biosciences, Buckinghamshire, England) using a
Trans-Blot SD apparatus (Bio-Rad, USA). The membrane was incubated with Blocking Buffer
(LI-COR Bioscience, Lincoln, NE, USA) and then with anti-TRP serum (1:2000 dilution), over-
night, at 4°C. After incubation with primary antibody, the membrane was incubated with bio-
tin anti-rabbit antibody (Santa Cruz Biotechnology, CA, USA) (1:1000 dilution) for 1 hour at
room temperature and then with streptavidin (Santa Cruz Biotechnology, CA, USA) (1:2000
dilution) for 30 minutes at room temperature for biotin-streptavidin binding. Anti-α-tubulin
(Sigma-Aldrich, St. Louis, MO, USA) (1:1000 dilution) was used to normalize the amount of
protein in the blot. All steps were followed by washing 3 times with PBS. The membranes were
scanned using an Odyssey CLx apparatus (Li-COR, Lincoln, NE, USA) in both 700 and 800
nm channels using an Odyssey System. Odyssey Imaging CLx instrument was used at the 5/5
intensity setting (700/800 nm). Quantification of the protein level was performed with Image
Studio2.1 Software (Li-COR, Lincoln, NE, USA). TRP target band densities were normalized
against α-tubulin for blotting comparisons in LmjF, cosTUB2 and pTRP transfectants. Statisti-
cal analysis was conducted using the Mann-Whitney U-test, and p< 0.05 was considered sig-
nificant for three independent experiments.
Confocal immunolocalization
Approximately 106 promastigotes of LmjF and pTRP transfectants in the stationary growth
phase were washed with PBS and adhered to cover slips treated with poly-L-lysine (Sigma-
Aldrich, St. Louis, MO, USA) for 15 minutes. The cells were then fixed with 3% paraformalde-
hyde for 10 minutes and treated with 50 mM ammonium chloride for 10 minutes. The fixed
cells were permeabilized and blocked with 0.1% Triton X-100 and 0.1% BSA in PBS for 10 min-
utes at room temperature. To analyze sub-cellular TRP localization, anti-TRP polyclonal anti-
body (1:100 dilution) was visualized using an anti-rabbit secondary antibody conjugated to
Alexa488 (Life Technologies, Carlsbad, CA, USA) (1:500 dilution). Anti-BiP/GRP78 (BD Bio-
science, Iowa, USA) (1:500 dilution) was visualized using an anti-mouse secondary antibody
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conjugated to Alexa594 (Life Technologies, Carlsbad, CA, USA) (1:500 dilution). Nuclear and
kinetoplast DNA were labeled using DAPI. Each step was followed by washing with PBS 10
times. The coverslips were mounted in ProLong media (Life Technologies, Carlsbad, CA,
USA). All imaging was performed at the Molecular Imaging Center (MIC) of the University of
Bergen, using a Zeiss LSM 510 Meta confocal microscopy. Co-localization images were edited
using Photoshop 6.
Results
Tubercidin resistance in cosTUB1 is due to the tor gene
Using the overexpression/selection strategy described by Cotrim et al. [21], a library of 17,900
independent genomic cosmid transfectants in LmjF were recovered from semisolid plates in
two TUB concentrations. Thirty-nine colonies showing differential survival were recovered
and then analyzed by restriction enzyme digestion. cosTUB1a and cosTUB1b were recovered
each one from a single colony, while cosTUB2 was recovered from several colonies [21].
Southern blot analysis demonstrated that cosTUB1a and cosTUB1b were involved in TUB
resistance conferred by the TOR protein [21]. This protein has been previously described as
related to TUB resistance in selected L. amazonensis promastigote mutants [22, 24]. Since cos-
TUB1a and cosTUB1b were referred to the same TUB resistance gene, we decided to examine
only cosTUB1a followed of mapping, functional and sequencing analysis.
Parasites transfected with the cosmid cosTUB1 showed moderate TUB resistance (1.95-fold
resistance) compared with the LmjF (S1 Table). To map the gene likely involved in the resis-
tance phenotype, a set of deletions was generated using the restriction enzyme KpnI. Four inde-
pendent deletions were generated, transfected back into LmjF and amplified by HYG selection.
Transfected parasites with the deletions cosTUB1-ΔKpnI-III and cosTUB1-ΔKpnI-IV exhib-
ited 2.04- and 2.82-fold resistance, respectively, compared with LmjF parasites (S1 Fig and S1
Table). No significant differences in resistance were observed among the other deletions com-
pared with LmjF or with transfected parasites carrying the empty vector cLHYG (S1 Table).
To identify the gene of cosTUB1 involved in TUB resistance, a 1.0 kb EcoRI fragment from
this cosmid (S1 Fig) was sub-cloned into the pUC-π vector and sequenced. In silico analysis
revealed that the cosTUB1 insert corresponds to a genomic DNA region from chromosome 31 of
LmjF containing five ORFs (S1 Fig). Two of which encode hypothetical proteins (LmjF.31.1910
and LmjF.31.1920), and the other three encode peptidase m20/m25/m40 family-like protein
(LmjF.31.1890), dihydrouridine synthase (LmjF.31.1930) and transcription-factor-like NUPM1
protein (LmjF.31.1940) (S1 Fig).
According to the map and the functional analysis, the 3.0 kb fragment represented in the
deletion cosTUB1-ΔKpnI-IV, contained the locus likely involved in TUB resistance (S1 Fig). In
this region, we identified the gene that encodes the transcription-factor-like NUPM1 protein
(LmjF.31.1940) (accession number XP_001685180.1) (S1 Fig). This protein has 77% similarity
to NUPM1 of L. amazonensis, which has been previously described as TOR protein and it is
related to TUB resistance in selected L. amazonensis promastigote mutants [22, 24]. According
to TriTrypDB, nupm1 encodes a 53.1 kDa protein with only one predicted transmembrane
domain and no other predicted domain (S2 Fig).
Tubercidin resistance in cosTUB2 is due to the trp gene
The other cosmid, cosTUB2, was recovered 37 times and presented a different resistance pro-
file compared with cosTUB1. It conferred a 3.78-fold increase in resistance compared with
LmjF (Table 1). Using the same strategy as that described for cosTUB1, we mapped the likely
gene involved in the resistance phenotype through the generation of a set of deletions with the
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restriction enzyme ApaI (Fig 1). Four independent deletions were generated, transfected back
into LmjF and then selected using HYG selection. Parasites transfected with the cosTUB2-
ΔApaI-III deletion exhibited 2.0-fold resistance compared with LmjF (Fig 1 and Table 1).
No significant difference was observed among the transfectants containing the other three
Table 1. TUB resistance profiles of cosTUB2 and its respective deletions compared with LmjF parasites.
Cell line IC50
(a) (μM) fold (b) resistance p value (c) TUB resistance
LmjF 0.23 ± 0.09 - - no
cLHYG 0.26 ± 0.06 1.13 ns no
pSNBR 0.30 ± 0.03 1.30 ns no
cosTUB2 0.87 ± 0.34 3.78 2x10-6 yes
cosTUB2-ΔApaI-I 0.27 ± 0.05 1.17 ns no
cosTUB2-ΔApaI-II 0.21 ± 0.07 0.91 ns no
cosTUB2-ΔApaI-III 0.46 ± 0.05 2.00 2x10-5 yes
cosTUB2-ΔApaI-IV 0.26 ± 0.09 1.13 ns no
pTRP 0.44 ± 0.08 1.91 0.002 yes
(a) Mean ± standard deviation of the IC50 values of at least three independent experiments for each indicated cell line.
(b) Fold-resistance is the ratio of the IC50 value for the respective transfected line and LmjF.
(c) p values versus LmjF according to the non-parametric Kruskal-Wallis test.
(ns)–not significant.
doi:10.1371/journal.pntd.0004972.t001
Fig 1. Restriction map of cosTUB2 and functional analysis. Linear representation of the cosTUB2 restriction map and
the four deletions generated by partial digestion with ApaI (A). The restriction sites of ClaI (C), EcoRI (EI) and EcoRV (E)
are also indicated in the Figure. TUB resistance is indicated by (+). The white arrows indicate the coding regions of the
hypothetical proteins (LmjF.31.2040, LmjF.31.2050 and LmjF.31.2060), non-coding RNA (LmjF.31.ncRNA), glycoprotein-
like (GP63-like) (LmjF.31.2000), succinyl-diaminopimelate-desuccinylase-like protein (SDD-like) (LmjF.31.2020) and
ubiquitin-fusion protein (LmjF.31.2030). The black arrow indicates the TRP gene (LmjF.31.2010). The shaded boxes
represent the cLHYG vector and the blank box represents the pSNBR vector.
doi:10.1371/journal.pntd.0004972.g001
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deletions compared with LmjF or with transfected parasites carrying the empty vector cLHYG
(Table 1).
To map the genomic region corresponding to the locus involved in TUB resistance, a 1.0 kb
EcoRV fragment from cosTUB2 (Fig 1) was sub-cloned into the pUC-π vector and sequenced.
Sequence analysis indicated that this DNA fragment corresponded to a second region of chro-
mosome 31 of L.major. In silico analysis indicated the presence of eight ORFs in the 30 kb geno-
mic region of cosTUB2. Four of these genes were annotated as encoding hypothetical proteins
(LmjF.31.2010, LmjF.31.2040, LmjF.31.2050 and LmjF.31.2060), while the other four genes
encoded a non-coding RNA (LmjF.31.ncRNA), a glycoprotein-like (GP63-like) (LmjF.31.2000),
a succinyl-diaminopimelate-desuccinylase-like (SDD-like) protein (LmjF.31.2020) and an ubi-
quitin-fusion protein (LmjF.31.2030) (Fig 1). In silico data associated with genomic mapping
and functional analysis indicated that the gene LmjF.31.2010, located in the 9.6 kb fragment of
cosTUB2 and also in cosTUB2-ΔApaI-III (Fig 1), encodes a hypothetical protein that could be
involved in TUB resistance.
To confirm LmjF.31.2010 as the gene involved with TUB resistance, we sub-cloned the
region encompassing the LmjF.31.2010 gene (a 3 kb fragment from cosTUB2 digested with
ClaI-EcoRI) into pSNBR vector, previously digested with the same enzymes (Fig 1). This con-
struct (pTRP) was transfected back into LmjF and the amplification and overexpression of this
gene was obtained by increasing the concentration of G418. As expected, the pTRP transfec-
tants exhibited 1.91-fold resistance compared with LmjF (Table 1), confirming the role of
LmjF.31.2010 gene in TUB resistance.
trpmRNA expression
The trpmRNA expression in LmjF promastigotes was measured by RT-qPCR. Quantification
of trp transcripts in the cosTUB2 and pTRP transfectants relative to LmjF or to the transfected
line with the empty vector (cLHYG or pSNBR) was performed using trp gene as target. The
data were normalized by the amount of gapdh transcript. Both sequences corresponded to sin-
gle copy genes. As shown in Fig 2, the cosTUB2 transfectant exhibited 19.4- and 16.8-fold
increase in trpmRNA expression compared with LmjF and with cLHYG transfectant, respec-
tively. In contrast, no significant change in trpmRNA expression was observed between the
pTRP transfectant and LmjF or pSNBR transfectant (Fig 2).
Additional data obtained during the time-course of growth curve of LmjF promastigotes
demonstrated that trp transcript expression was increased in the day 3, in the logarithimic
growth phase. As shown in S3 Fig, trpmRNA transcript expression was 2-fold increase on day
3 compared with days 5, 7 and 9. The same profile was observed at protein levels, with an
increase of 1.5-fold on day 3 compared with days 5, 7 and 9 (S3 Fig).
TRP expression in promastigotes
Western blot analysis of cell lysates from LmjF and parasites transfected with cosTUB2 and
pTRP were performed using an anti-TRP polyclonal antibody. As shown in Fig 3, the signal
intensity of TRP expression was significantly increased in the cosTUB2 and pTRP lysates com-
pared with LmjF lysate.
Predictions for TRP
Sequence analysis of the trp gene (LmjF.31.2010) (accession number XP_001685187.1) indi-
cated that it encodes a 63.4 kDa protein. It is conserved in the genus Leishmania, and it is not
present in other trypanosomatids, such as Trypanosoma brucei and T. cruzi (Fig 4). This gene
encodes for a protein that contains just one hypothetical transmembrane domain and no
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other putative conserved domain or peptide signal (S4 Fig). Interestingly, multiple sequence
alignments revealed the presence of 11 amino acids specific to L. braziliensis (LbrM) (S4 Fig).
Indeed, TRP of L.major contains approximately 85% of similarity with its orthologs of the
subgenus Leishmania and 54% of similarity with its ortholog of L. (Viannia) braziliensis
(S4 Fig).
Additional in silico data based on the Protein Functional Category and Enzyme Class Data-
base (ProtFun Server), which predicts cellular role and enzyme class based on gene ontology,
indicated that TRP is an enzyme involved in the purine and pyrimidine pathway. In silico anal-
ysis of TRP using the TargetP 1.1 Server, which predicts the sub-cellular localization of eukary-
otic proteins revealed the absence of any sequence corresponding to a mitochondrial targeting
peptide.
3D protein prediction was performed by submitting the amino acid sequence to the Phyre2
web portal for protein modeling, prediction and analysis. The predicted model of TRP based
on heuristics to maximize confidence, percent identity and alignment coverage is shown in Fig
5. Some disordered regions were observed, but the prediction showed 90% confidence. Some
regions have interesting folding patterns with similarities to transmembrane helices, multidrug
efflux transporter, hydrolase/transport protein and transferase (Fig 5).
Immunolocalization of TRP
For cellular immunolocalization of TRP, we used antibodies against the recombinant TRP.
Considering our hypothesis that TRP is an ER protein, we used an ER marker (anti-BiP/
GRP78). Confocal microscopy showed that TRP is co-localized in ER in stationary phase pro-
mastigotes of LmjF and of pTRP transfected line (Fig 6).
Fig 2. Evaluation of trpmRNA expression. trpmRNA expression in promastigotes of LmjF, and the lines
transfected with the cLHYG vector, cosTUB2, pSNBR vector and pTRP were determined by trp-specific RT-
qPCR. Data were based on quantification of the target and were normalized by gapdh expression. (*)
p < 0.0001, compared with the line transfected with the vector cLHYG or with LmjF. The values are the
mean ± SEM of three independent biological replicates.
doi:10.1371/journal.pntd.0004972.g002
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Analysis of cross-resistance profiles against anti-leishmanial drugs
We next analyzed whether the transfected lines overexpressing the trp gene were resistant to
other drugs. Interestingly, the cosTUB2 and pTRP transfectants showed cross-resistance to
pentamidine, with 2.0- and 5.0-fold resistance, respectively, compared with LmjF (Table 2). No
cross-resistance to allopurinol was observed. Indeed, the cosTUB2 transfectants were more
sensitive to allopurinol.
Discussion
The molecular mechanism of action of compounds used in leishmaniasis treatment is not well
known. Overexpression/selection methods have been used for identification of drug targets
Fig 3. TRP expression in transfectant lines, as determined byWestern blotting. Total extracts of
promastigotes in the stationary phase for LmjF, cosTUB2 and pTRP transfectants were lysed and the
proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted with an
anti-TRP polyclonal antibody. An anti-α-tubulin antibody was used as a control. The images were scanned
using an Odyssey CLx imaging system (Li-COR). (A) Western blot analysis of LmjF, cosTUB2 and pTRP
transfectants. (B) The bands were quantified using Image Studio2.1 Software (Li-COR) and the results for
TRP were normalized against α-tubulin for blotting comparisons. Statistical analysis was performed using
Mann-Whitney U test. (*) p < 0.05, compared with LmjF.
doi:10.1371/journal.pntd.0004972.g003
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and potential drug resistant genes [21, 30, 31, 41]. Because of the limited knowledge about the
purine metabolism in Leishmania, we proposed in this study to elucidate the purine pathway
in Leishmania examining the resistance phenotype after transfection of a cosmid genomic
library, followed by drug pressure using TUB. This drug has been demonstrated to have potent
activity against promastigotes forms of L. amazonensis, L. braziliensis, L. infantum chagasi and
L.major [19, 20]. The same antiparasitic efficacy has also been reported in vitro against intra-
cellular amastigotes and in vivo infection against L. amazonensis when the drug was associated
with the specific inhibitor of nucleoside transport for mammalian cells, the nitrobenzylthioino-
sine (NBMPR) [20].
Two cosmids conferring TUB resistance, cosTUB1 and cosTUB2, were isolated from trans-
fected parasites with a genomic library constructed in the cLHYG vector [21]. The gene related
to TUB resistance in cosTUB1 provided 2.82-fold resistance compared with LmjF. In silico anal-
ysis of the genomic region in L.majorGeneDB revealed that cosTUB1 is located on chromo-
some 31 and that 1,455 base pair gene present in the 3.0 kb fragment encodes NUPM1-like
Fig 4. Mapping and alignment of the genomic region around trp gene for six Leishmania species.Map of the genomic region of
cosTUB2 from L.major Friedlin (LmjF) and localization of the trp gene (LmjF.31.2010) in comparison with the following Leishmania spp.,
according to TriTrypDB: L. (V.) braziliensisMHOM/BR/75/M2904 (LbrM), L. (L.) donovani BPK282A1 (LdBPK), L. (L.) infantum JPCM5
(LinJ), L. (L.) mexicanaMHOM/GT/2001/U1103 (LmxM), L. (L.) tarentolae Parrot-TarII (LtaP). The white arrows indicate the coding
regions of hypothetical proteins (LmjF.31.2040, LmjF.31.2050 and LmjF.31.2060), non-coding RNA (LmjF.31.ncRNA), glycoprotein-like
63 (GP63-like) (LmjF.31.2000), succinyl-diaminopimelate-desuccinylase-like (SDD-like) protein (LmjF.31.2020) and the ubiquitin-fusion
protein (LmjF.31.2030). The black arrow indicates the trp gene (LmjF.31.2010).
doi:10.1371/journal.pntd.0004972.g004
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protein. A previous study first referred to this protein as TOR because it was involved in TUB
resistance in selected L. amazonensismutants [23]. According to these authors, L. amazonensis
becomes resistant to TUB by decreasing the capacity to accumulate this exogenous purine.
Later, it was suggested that the decrease was related to the reduction in the activity of purine
Fig 5. Structural prediction of the TRP. Protein modeling, prediction and analysis, according to Phyre2 web
portal for TRP. The predicted protein contains 36% alpha helix, 6% beta strand and 3% transmembrane helix, in
addition to multidrug efflux transporter, hydrolase/transport protein and transferase folds.
doi:10.1371/journal.pntd.0004972.g005
Fig 6. Cellular localization of TRP in L.major. Promastigotes in the stationary phase of LmjF and transfected line with pTRP showing
phase-contrast image, DNA staining using DAPI (blue), anti-TRP polyclonal antibody visualized with an anti-rabbit secondary antibody
conjugated to Alexa488 (green), anti-BiP/GRP78 visualized with an anti-mouse secondary antibody conjugated to Alexa594 (red) and
merged image. All images were acquired using a Zeiss LSM confocal microscope. Bar 10μm.
doi:10.1371/journal.pntd.0004972.g006
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transporters [24]. The TOR protein mediates resistance by redirecting the adenosine permease
from the plasma membrane to the multi-vesicular tubule lysosome [24] and TUB resistant para-
sites overexpressing tor are unable to uptake the toxic purine and become resistant to the drug
[24]. Moreover, TOR could act at the protein level and affect the activity and/or the amount of
transporters and other proteins [24]. The protein has similarities to Oct-6, a mammalian tran-
scription factor of the Pou family [24, 42]. Members of the Oct family bind to the octamer motif,
a cis-acting regulatory element enhancer and stimulate transcription via this octamer motif [42].
In contrast to TOR identification, we could not find any previously described gene in cos-
TUB2 related to TUB resistance. Similar to cosTUB1, the cosTUB2 insert contains a genomic
region of chromosome 31, but the region is distinct from that one in cosTUB1. According to
the restriction map and functional analysis, the 9.6 kb fragment present in both cosTUB2 and
the cosTUB2-ΔApaI-III deletion was suggested to be the region related to TUB resistance. In
silico analysis showed that this region coded for a hypothetical protein (LmjF.31.2010), a succi-
nyl-diaminopimelate-desuccinylase-like (SDD-like gene) and part of the glycoprotein 63
(GP63-like). GP63-like is the major surface glycoprotein in Leishmania promastigotes, beside
lipophosphoglycan (LPG) and GIPLs [43]. Several functions of GP63 have been described in
the vertebrate host, including cell adhesion to mammalian cells. It is predominantly expressed
in the form present in the insect host and unknown relationship with drug resistance or purine
metabolism has been described. Further, SDD-like is not either associated with resistance to
toxic nucleosides. Its function is related to synthesis and metabolism of amino acids [44].
Thus, we focused our study on the hypothetical protein LmjF.31.2010. The coding region of
this gene was cloned for generating the construct pTRP, which was transfected into LmjF. The
protocol for overexpression/selection of transfectants conferred moderate level of resistance to
TUB (1.91-fold resistance) compared with that conferred by cosTUB2 (3.78-fold resistance).
Despite the low level of resistance mediated by pTRP, there are several indications that trp is
involved in TUB resistance. First, the signals for protein translation were intact. Second, the
levels of resistance were significant for cosTUB2 (with a 30 kb insert), cosTUB2-ΔApaI-III
(with a 26 kb insert) and pTRP (with a 3 kb insert). Third, genes that conferred resistance by
transfection to other drugs, such as terbinafine and itraconazol [21], vinblastina [45], prima-
quine [46], pentamidine [30], antimony, miltefosine and amphotericin [41] presented a mod-
erate resistance profile as observed for trp gene. As an example, the squalene synthetase gene
(sqs1) has been identified in a cosmid that conferred resistance to terbinafine (1.47-fold resis-
tance) in L.major [21].
The analysis of trp transcripts revealed that the RNA level was increased in cosTUB2 com-
pared with LmjF. In contrast, we observed similar RNA expression levels when comparing
pTRP transcripts. Interesting, the increased resistance level conferred by cosTUB2 (3.78-fold
resistance) versus pTRP (1.91-fold resistance) was not correlated with the relative trpmRNA
Table 2. Cross-resistance profiles of cosTUB2 and pTRP transfectants compared with LmjF parasites.
IC50
(a) fold-resistance (b)
Drug LmjF cosTUB2 pTRP cosTUB2 pTRP
tubercidin (μM) 0.23 ± 0.09 0.87 ± 0.34 0.44 ± 0.08 3.78 2.00
allopurinol (μg/mL) 34.6 ± 6.05 19.0 ± 1.41 ND 0.54 -
pentamidine (μg/mL) 0.65 ± 0.07 1.35 ± 0.04 3.26 ± 0.60 2.03 5.01
(a) Mean ± standard deviation of IC50 values from at least three independent experiments for each indicated line.
(b) Fold-resistance is the ratio of the IC50 value for the transfectants and LmjF.
(ND)—Not done.
doi:10.1371/journal.pntd.0004972.t002
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abundance. These results indicate that trp expression could be subjected to some negative regu-
lation. The increased transcription of trp in cosTUB2 transfectants compared with pTRP trans-
fectants can be explained by the action of cis and trans elements as regulatory factors of mRNA
generated by cosTUB2 and pTRP. Moreover, cosmids may contain regulatory sequences that
are missing in the plasmid. Indeed, the length of the cosmid DNA can provide a chromatin-
like structure that allows to enhance the transcription and consequently promote an increase
in protein translation [47].
Western blot analysis revealed that the protein levels differed between LmjF and the trans-
fected lines (cosTUB2 and pTRP), with an increase of TRP expression in the transfected lines.
The sub-cellular immunolocalization of TRP in the ER suggests that it is associated with the
secretory pathway [48]. Proteins located in the ER may be related to the stress response, the
downregulation of translation, spliced leader silencing and protein misfolding [49].
In addition, GFP-tagged TOR has been previously demonstrated to be present at multiple
locations in Leishmania (i.e., mitochondria and Golgi/trans Golgi regions) except the nucleus
[24]. TOR appears to act at the protein level and affect the activities and/or concentration of a
class of transporters and other proteins [24]. TUB is transported by adenosine permease, but
this purine analog, which is toxic to the parasite, must first enter the cell. According to Detke
et al. (2007), parasites become resistant to this toxic purine nucleoside due to the functional
loss of the appropriate transporter by mutation or amplification of the tor gene, which leads to
a decrease of TUB entry into the cell [24].
Nucleoside transport in Leishmania is mediate by transporters located in the plasma mem-
brane of the parasite. There are five different members that have different and selective sub-
strate specificities [14]. The regulation of these transporters occurs via salvage pathway because
Leishmania does not synthesize purine de novo [10]. The nucleoside transporters of L. dono-
vani, LdNT1.1 and LdNT1.2, were previously described. Both transporters mediate adenosine
and pyrimidine uptake [15, 50], they are members of the equilibrative nucleoside transporter
(ENT) family [51, 52] and exhibit approximately 30% amino acid identity with mammalian
ENTs [10]. This low identity is due to differences in the nucleoside transporter members
between Leishmania and the mammalian host. It has been previously demonstrated that the
use of TUB in association with the nucleoside transport inhibitors can result in highly selective
toxicity against the parasite, thereby protecting the host against TUB toxicity [20]. LmaNT3
transporter from L.major was reported with a homology of LdNT1.1 with 33% amino acid
sequence identity [53]. It mediates the hypoxanthine, xanthine, adenine and guanine uptake.
Interestingly, its functions are optimal at neutral pH in the promastigote form [54]. In contrast,
LmaNT4 has very low transport activity at neutral pH, but it is functional in the acid pH that is
found within acidified phagolysomal vesicles of host macrophages during the intracellular
amastigote stage of the parasite [54].
It was also demonstrated that Leishmania overexpressing adenosine permease exhibits an
increased sensitivity to TUB [24]. In contrast, resistance to TUB occurs due to functional loss
of adenosine and guanosine permease through mutation or amplification of the tor gene [22–
24]. The reduction in adenosine permease is due to reduction in the amount of transporter per
se and to the re-routing of the normal trafficking of this transporter from the plasma mem-
brane to the multi-vesicular tubule lysosome [24].
Even in relation to the nucleoside transporters, we hypothesize that the cross-resistance to
pentamidine exhibited by cosTUB2 and pTRP transfectants is TRP-dependent. It has been
reported that several of the 12 ENTs family identified in T. brucei with involvement in the sal-
vage pathway can also transport pentamidine [54]. Pentamidine is a second-line drug used as
an alternative to the leishmaniasis treatment with pentavalent antimony. The drug enters into
the Leishmania promastigote or amastigote via a high affinity pentamidine transporter [55].
Tubercidin Resistance in Leishmania
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004972 September 8, 2016 15 / 21
The mitochondrion is an important target and the drug is involved in the binding and disinte-
gration of kinetoplast DNA [56–58]. Integration of the pathways involved in TUB and pentam-
idine resistance can be reinforced by the immunolocalization of TRP close to the perinuclear
network, although additional studies are required to elucidate this relationship. In contrast, no
cross-resistance was observed for allopurinol. Allopurinol is known to inhibit enzymes of the
purine salvage pathway in Leishmania [59]. The mechanism of action of allopurinol is involved
in the conversion to ribonucleoside triphosphate analogs and incorporation into RNA, thereby
disrupting macromolecular biosynthesis [60]. Interestingly, TRP overexpression led to a 2-fold
increase in allopurinol susceptibility [21].
Three other hypothetical proteins (LmjF.31.2040, LmjF.31.2050 and LmjF.31.2060), non-
coding-RNA (LmjF.31.ncRNA) and ubiquitin-fusion protein (LmjF.31.2030) were identified in
cosTUB2. Although the term ncRNA is commonly used for RNA that does not encode a pro-
tein, it does not mean that the RNA has no genetic information and function. It has been
described studies of the involvement of ncRNAs in RNA splicing, editing, translation and turn-
over [61]. In contrast, ubiquitin is a conserved protein, with a difference of only 3 amino acids
between Saccharomyces cerevisiae and humans [62]. Protein ubiquitylation is a recognized sig-
nal for protein degradation that can control post-translational modifications [55]. It is also
known that internalization and retargeting of membrane proteins is frequently initiated by ubi-
quitination [63, 64]. Although LmjF.31.ncRNA and LmjF.31.2030 were represented in cos-
TUB2-ΔApaI-I and cosTUB2-ΔApaI-IV, respectively, no TUB resistance per se was observed.
We also verified that TRP contains only one hypothetical transmembrane domain and no
putative conserved domain. The identification of a single hypothetical transmembrane domain
confirms our co-localization, indicating that it is not a membrane transporter, in contrast with
the ENTs described in Leishmania that contain 11 hypothetical transmembrane domains [52,
65]. The location of the transmembrane domain of TRP in the C-terminal region suggests that
this protein can be anchored. Comparative analysis based in TriTrypDB demonstrated that trp
is specific in the genus Leishmania, with no ortholog identified in T. brucei or T. cruzi. In silico
analysis revealed that trp gene is located in the same genomic region of chromosome 31 of L.
infantum (LinJ.31.2050), L. tarantolae (LtaP.31.2440) and L. braziliensis (LbrM.31.2270).
According to TriTrypDB, trp gene is constitutively expressed, however our findings demon-
strated that trp is more expressed in logarithmic phase. This result can emphasize the likely
relation with purine pathway and the potential role of this protein during the replication of the
parasite. All these results indicate the importance of characterizing a hypothetical protein not
only by functional genomics, but also according to its general biological features, allowing the
acquisition of new knowledge about signaling pathways, metabolism, stress response, drug
resistance and in the identification of new therapeutic targets. Purine transport can be consid-
ered a potential target, since the mechanism of action is different in Leishmania and its host.
Aoki et al. (2009) demonstrated that the association with a specific inhibitor of the nucleoside
transport for mammalian cells, NBMPR, protects infected mammalian host from the toxic
effects of TUB. NBMPR inhibits only the mammalian nucleoside transport, thus protecting the
host and not the parasite from the TUB toxicity, similarly as proposed in Schistosomamodel
[16, 17].
In conclusion, the TRP, initially annotated as a hypothetical protein was described in this
work as involved with TUB resistance.
Supporting Information
S1 Fig. Restriction map of cosTUB1 and functional analysis. Linear representation of cos-
TUB1 restriction map insert and the four deletions generated by partial digestion with KpnI (K).
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The restriction sites of EcoRI (EI) are also indicated in the figure. TUB resistance is indicated by
(+) sign. The white arrows indicate the coding region of the peptidase m20/m25/m40 family-
like protein (LmjF.31.1890), the hypothetical proteins (LmjF.31.1910 and LmjF.31.1920), and
the dihydrouridine synthase (DUS) (LmjF.31.1930). The black arrow indicates the transcrip-
tion-factor-like protein (nupM1) (LmjF.31.1940), also known as TOR. The shaded boxes repre-
sent the cLHYG vector.
(TIF)
S2 Fig. Alignment of the transcription-factor-like protein (LmjF.31.1940) from L.major
with their orthologs of Leishmania spp.Multiple alignment of amino acid sequence of
the transcription-factor-like protein of L.major Friedlin (LmjF), L. (L.) tarentolae Parrot-
TarII (LtaP), L. (V.) braziliensisMHOM/BR/75/M2904 (LbrM), L. (L.) infantum JPCM5
(LinJ), L. (L.) mexicanaMHOM/GT/2001/U1103 (LmxM), L. (L.) donovani BPK282A1
(LdBPK). The identical amino acids are highlighted in gray and the transmembrane domain
is boxed.
(TIF)
S3 Fig. Evaluation of TRP in mRNA transcripts expression and protein expression levels
during time-course of L.major growth curve. (A) Symmetrical sigmoidal nonlinear regres-
sion curve of LmjF during time-course of growth. The values are the mean ± SEM of three
independent biological preparations. (B) TRP mRNA expression level of promastigotes LmjF.
Data were based on the quantification of target and normalized by GAPDH data. () p<
0.005, () p< 0.002, () p< 0.001, compared the day 3 to that on days 5, 7 and 9, respec-
tively. The values are the mean ± SEM of three independent biological preparations. (C) West-
ern blot analysis of total extract of promastigotes during time-course of LmjF. The extracts
were lysed and then proteins were separated by SDS-PAGE, transferred to nitrocellulose mem-
brane and immunoblotted with anti-TRP polyclonal antibody. The anti-α-tubulin antibody
was used as a control. The images were scanned using an Odyssey CLx imaging system (Li-
COR). (D) The bands were quantified using Image Studio2.1 Software (Li-COR), and the
results for TRP were normalized against α-tubulin for blotting comparisons. Statistical analy-
sis was performed using Mann-Whitney U test. () p< 0.05, () p< 0.001, comparing the
day 3 with days 5, 7 and 9.
(TIF)
S4 Fig. Alignment of TRP (LmjF.31.2010) from L.major with their orthologs of Leish-
mania spp.Multiple alignment of amino acid sequence of the TRP of L.major Friedlin (LmjF),
L. (L.) tarentolae Parrot-TarII (LtaP), L. (V.) braziliensisMHOM/BR/75/M2904 (LbrM), L. (L.)
infantum JPCM5 (LinJ), L. (L.) mexicanaMHOM/GT/2001/U1103 (LmxM) and L. (L.) dono-
vani BPK282A1 (LdBPK). The identical amino acids are highlighted in gray and the trans-
membrane domain is boxed.
(TIF)
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